Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
BiotechTV: Kymera Therapeutics’ Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company’s STAT6 healthy volunteer data
Biopharma Dive: Kymera, with new data, takes early step toward a Dupixent-like pill
Endpoints News: Kymera unveils ‘exceptional’ Phase 1 data for its Dupixent-in-a-pill program
STAT News: Kymera reports early-stage success for drug meant to rival Sanofi and Regeneron’s Dupixent
BiotechTV: State of Possible, Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company’s programs, including a new one to come
Our CEO, Nello Mainolfi, provides an overview of Kymera’s approach, pipeline, and upcoming milestones.
Nature Reviews Drug Discovery: Protein Degraders Push into Novel Target Space
Our CEO, Nello Mainolfi, was interviewed by Nature Reviews Drug Discovery to discuss how targeted protein degradation can unlock previously intractable disease targets, including our STAT6 and IRAK4 degraders in immunology.
PharmaVoice 100 Top Industry Leaders: Dr. Jared Gollob, Chief Medical Officer
A physician by training, Dr. Jared Gollob’s biopharma career has been rooted in the belief that patients’ needs come first. And it’s one he carries with him as chief medical officer of Kymera Therapeutics, a clinical-stage biotech targeting diseases once considered undruggable.
Dermatology Times: Study Highlights KT-474’s Effectiveness in Targeting IRAK4 for Hidradenitis Suppurativa and Other Inflammatory Diseases
Dermatology Times spoke with Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, to discuss the role of IRAK4 expression and degradation in HS, as well as the potential of KT-474 in immuno-inflammatory diseases.
BiotechTV: Nello Mainolfi Shares an Update on Kymera and the Progress of the Protein Degradation Field
Nello gives updates on programs such as IRAK4, STAT6, TYK2, and STAT3, and describes learnings in protein degradation that Kymera has discovered since the last time BiotechTV visited the company one year ago.